TY - CONF T1 - Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial JO - Blood PY - 2015/12/03 AU - Ashcroft J AU - Cairns DA AU - Williams C AU - Hockaday A AU - Cavenagh JD AU - Snowden JA AU - Parrish C AU - Yong KL AU - Cavet J AU - Hunter H AU - Bird J et al ED - DO - DOI: 10.1182/blood.v126.23.1981.1981 PB - American Society of Hematology VL - 126 IS - 23 SP - 1981 EP - 1981 Y2 - 2025/04/09 ER -